Acer therapeutics and relief therapeutics announce presentation of acer-001 data at the genetic metabolic dieticians international conference

Newton, mass. and geneva, may 06, 2022 (globe newswire) -- acer therapeutics inc. (nasdaq: acer) (“acer”) and its collaboration partner, relief therapeutics holding sa (six: rlf, otcqb: rlftf, rlfty) (“relief”), today announced the presentation of data evaluating the bioavailability, bioequivalence and taste attributes of acer-001 (sodium phenylbutyrate) compared to sodium phenylbutyrate (buphenyl®) powder during poster sessions at the recent genetic metabolic dieticians international (gmdi) conference on may 5, 2022, in las vegas, nevada.
ACER Ratings Summary
ACER Quant Ranking